Fundraising FoxHDL Therapeutics
Vero Beach, US · Founded 2013 · Delaware corporation
Find your way into HDL Therapeutics
Sign up to see every warm intro you have to HDL Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the HDL Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
HDL Therapeutics is a commercial-stage biotechnology company with an FDA-approved therapy that reduces coronary atheroma in a rare cardiovascular disease. The company develops therapies targeting cardiovascular, neurodegenerative, autoimmune, viral, and peripheral vascular diseases.
Founders & leadership
DB
Dr. Bryan BrewerChief Scientific Officer
MA
Michael A. MatinChairman & CEO
HB
H. Bryan BrewerChief Scientific Officer
TJ
Timothy J. PerlmanChief Technology Officer
MM
Michael McCannChief Commercial Officer
LA
Lori A. CarrVP, Quality Management & Regulatory Affairs
Reported raises · per SEC filings
Form D private placements$16.9M disclosed across 5 rounds · 2014–2023
▶$1.3MraisedJul 2023 · 15 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJul 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael MatinExecutive Officer
- Gregg SessaDirector
- Dane AndreeffDirector
- Bryan BrewerExecutive Officer
- Offering amount
- $7M
- Amount sold
- $1.3M
- Proceeds to insiders
- $277K
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedMar 2021 · 31 investors · BiotechnologyRule 506(b)
▶$3.4MraisedMar 2021 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dane AndreeffDirector
- Bryan BrewerExecutive Officer, Director
- Michael MatinExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $3.4M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedOct 2019 · 34 investors · BiotechnologyRule 506(b)
▶$3MraisedOct 2019 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael MatinExecutive Officer, Director
- Dane AndreeffDirector
- Bryan BrewerExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.2MraisedMay 2017 · 57 investors · BiotechnologyRule 506(b)
▶$7.2MraisedMay 2017 · 57 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bryan BrewerExecutive Officer, Director
- Michael MatinExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $7.2M
- Sales commissions
- $187.7K
- Proceeds to insiders
- $400K
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$2MraisedDec 2014 · 14 investors · BiotechnologyRule 506(b)
▶$2MraisedDec 2014 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael MatinExecutive Officer, Director
- Bryan BrewerExecutive Officer, Director
- Offering amount
- $4.6M
- Amount sold
- $2M
- Proceeds to insiders
- $500K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
Quest DiagnosticsQuest Diagnostics is the world's leading provider of diagnostic information services, serving one in three adult Americans and half of US physicians and hospitals. The company offers diagnostic insights and testing services to consumers and healthcare providers to support health decision-making.
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Companies working in the same space as HDL Therapeutics.
Frequently asked questions
- What does HDL Therapeutics do?
- HDL Therapeutics is a commercial-stage biotechnology company with an FDA-approved therapy that reduces coronary atheroma in a rare cardiovascular disease. The company develops therapies targeting cardiovascular, neurodegenerative, autoimmune, viral, and peripheral vascular diseases.
- How much funding has HDL Therapeutics raised?
- HDL Therapeutics has disclosed $16.9M raised across 5 rounds.
- Where is HDL Therapeutics headquartered?
- HDL Therapeutics is headquartered in Vero Beach, US.